Research programme: histamine H3 receptor antagonists - Abbvie
Alternative Names: A 320436; A 349821; A 431404Latest Information Update: 30 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Piperazines
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders; Pain
- Discontinued Attention-deficit hyperactivity disorder